Synthetic Biologics Sinks 14% On Phase 2 Trial Failure For Relapsing-Remitting Multiple Sclerosis
February 03, 2016 at 02:39 AM EST
With these clinical findings, the company has chosen to abandon the Trimesta program and focus clinical resources on two gut microbiome programs.
